drugset
Drugs / JEV-GCC
last change Jan 2015 re-read 3 minutes ago

JEV-GCC

Vaccine

Developed for
Japanese encephalitis
Investigated by
Boryung Pharmaceutical Co., Ltd · Ewha Womans University · Gachon University Gil Medical Center · Inha University Hospital · Inje University · Korea Cancer Center Hospital
+5 more · Kyunghee University Medical Center · Samsung Medical Center · Seoul National University Hospital · The Catholic University of Korea · Wonju Severance Christian Hospital

Trials 1

today NCT01150942 · Ph 3
20112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT01150942 Aug 2010 → Sep 2012 Japanese encephalitis Boryung Pharmaceutical Co., Ltd Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as JEV-GCC “In a phase III clinical study, we aimed to compare the safety and immunogenicity of a JE-VC, KD-287 with a JE-MB, JEV-GCC, in children.” PMID 25567119 ↗ Jan 2015
Modality Vaccine “mouse brain-derived inactivated Japanese encephalitis vaccine” PMID 25567119 ↗ Jan 2015
Route Intramuscular “3 times, IM” NCT01150942 ↗